[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365699-105":59,"doc-detail-365699-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-and-validation-of-an-arid1a-related-immune-genes-risk-model-in-evaluating-prognosis-and-immune-therapeutic-efficacy-for-gastric-cancer-patients-a-translational-study","Development and validation of an ARID1A-related immune genes risk model in evaluating prognosis and immune therapeutic efficacy for gastric cancer patients: a translational study","","ARID1A mutations in the SWI/SNF chromatin remodeling pathway are common in gastric cancer and can influence both patient outcomes and immune responses. This translational study identifies ARID1A mutation-associated immune genes, builds an ARID1A-related immune gene risk model, and evaluates prognosis. The model is developed with TCGA-STAD training/testing cohorts, validated across TCGA and multiple GEO cohorts plus clinical patients. Differences in immune microenvironment and immune checkpoint inhibitor response markers distinguish risk groups, while APOD/PROC and candidate compounds support therapeutic relevance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-and-validation-of-an-arid1a-related-immune-genes-risk-model-in-evaluating-prognosis-and-immune-therapeutic-efficacy-for-gastric-cancer-patients-a-translational-study/365699/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-and-validation-of-an-arid1a-related-immune-genes-risk-model-in-evaluating-prognosis-and-immune-therapeutic-efficacy-for-gastric-cancer-patients-a-translational-study/365699.png","ImageObject",300,407,{"name":92,"@type":93},"Sophia Brooks","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study?","Question",{"text":112,"@type":113},"To identify ARID1A mutation-associated immune genes and construct an ARID1A-related immune gene risk model for assessing prognosis and immune therapeutic efficacy in gastric cancer patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the risk model constructed and validated?",{"text":117,"@type":113},"The prognosis model was built using lasso-COX, developed in TCGA-STAD training cohorts, and validated across TCGA and five GEO cohorts as well as clinical samples from Hainan General Hospital.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune-related findings distinguish the ARID1A mutation groups and risk groups?",{"text":121,"@type":113},"Immune-related pathways and multiple immune cell infiltration levels are enriched in the ARID1A-mutant group. High- and low-risk groups show different tumor immune microenvironment components and markers linked to immune checkpoint inhibitor efficacy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365699,1790198015,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TYPE Original Research PUBLISHED 28 April 2025  \nDOI 10.3389/fimmu.2025.1541491  \nOPEN ACCESS  \nEDITED BY  \nMassimiliano Petrini,  \nScientiﬁc Institute of Romagna for the Study and Treatment of Tumors (IRCCS), Italy  \nREVIEWED BY  \nBiswarup Basu,  \nChittaranjan National Cancer Institute (CNCI), India  \nLe Zhang,  \nCedars Sinai Medical Center, United States Munna Lal Yadav,  \nIndian Council of Medical Research (ICMR), India  \n*CORRESPONDENCE  \nXiaoling Gao  \n [gaoxl008@hotmail.com](gaoxl008@hotmail.com)  \n†These authors have contributed equally to this work  \nRECEIVED 07 December 2024  \nACCEPTED 07 April 2025  \nPUBLISHED 28 April 2025  \nCORRECTED 13 June 2025  \nCITATION  \nZhang J, Li J, Yang S, Tang X, Wang C, Lin J, Chen Q, Xu H, Ma Y and Gao X (2025) Development and validation of an ARID1Arelated immune genes risk model in evaluating prognosis and immune therapeutic efﬁcacy for gastric cancer patients: a translational study.  \nFront. Immunol. 16:1541491 .  \ndoi: 10.3389/fimmu.2025.1541491  \nCOPYRIGHT  \n© 2025 Zhang, Li, Yang, Tang, Wang, Lin, Chen, Xu, Ma and Gao. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nDevelopment and validation of an ARID1A-related immune genes risk model in evaluating prognosis and immune therapeutic efﬁcacy for gastric cancer patients: a translational study  \nJiangtao Zhang 1,2†, Jingting Li 1,2†, Shangfeng Yang 2†, Xiaoyan Tang 1,2, Chunze Wang 1,2, Jiaxing Lin 1,2,  \nQiancheng Chen 2, Hui Xu 1, Yuanyuan Ma 3 and Xiaoling Gao 1,2*  \n1The Clinical Laboratory Center, Hainan General Hospital, Hainan Afﬁliated Hospital of Hainan Medical University, Haikou, Hainan, China, 2 Hainan Medical University, Haikou, Hainan, China, 3Second Department of Critical Care Medicine, Xi ’an Daxing Hospital, Shanxi, China  \nBackground: Mutations in the ARID1A gene, an integral component of the SWI/ SNF complex, are prevalent, affecting prognosis and immune response in several malignancies, including gastric cancer (GC). The aim of this study was to identify ARID1A mutation-associated immune genes to construct an ARID1A-related immune gene risk model (ARM) .  \nMethods: GSEA and ssGSEA were used to explore the involved biological pathways and the degree of immune cell inﬁltration, respectively. The prognosis model was constructed by lasso-COX. Protein expression level in tissue was veriﬁed by immunohistochemistry. Small molecule compounds were screened using molecular docking techniques and their anticancer value was validated in vitro and in vivo experiment.  \nResults: This study revealed immune-related pathways and inﬁltration level of multiple immune cell types were enriched in the ARID1AMUT group compared to the ARID1AWT group. ARID1A mutations were correlated with an improved prognosis in individuals treated with immune checkpoint inhibitor (ICI) analyzed via Cbioportal website. TCGA-STAD cohort was randomly divided into a training-group and a testing-group. Additionally, ARM was developed in the training group, which identiﬁed APOD and PROC from ARID1A mutationassociated differential immunity genes. A signiﬁcantly poorer prognosis in the high-risk group compared to the low-risk group, which was consistent across TCGA-training/testing/all cohorts, ﬁve GEO cohorts and 55 GC patients from Hainan General Hospital. Furthermore, the immune microenvironment components and ICI therapeutic efﬁcacy markers were different between the two groups. Meanwhile, APOD and PROC expression was higher in GC tissues compared to para-cancerous tissues. Baicalin and capsaicin inhibited the proliferation and metastatic ability of GC cells","cbCaivEJNMyA79vn","https://ap.wps.com/l/cbCaivEJNMyA79vn","pdf",32049068,15,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What is the main goal of this study?\",\"answer\":\"To identify ARID1A mutation-associated immune genes and construct an ARID1A-related immune gene risk model for assessing prognosis and immune therapeutic efficacy in gastric cancer patients.\"},{\"question\":\"How was the risk model constructed and validated?\",\"answer\":\"The prognosis model was built using lasso-COX, developed in TCGA-STAD training cohorts, and validated across TCGA and five GEO cohorts as well as clinical samples from Hainan General Hospital.\"},{\"question\":\"What immune-related findings distinguish the ARID1A mutation groups and risk groups?\",\"answer\":\"Immune-related pathways and multiple immune cell infiltration levels are enriched in the ARID1A-mutant group. High- and low-risk groups show different tumor immune microenvironment components and markers linked to immune checkpoint inhibitor efficacy.\"}]","Development and validation of an ARID1A-related immune genes risk model in evaluating prognosis and immune therapeutic efficacy for gastric cancer patients: a translational study | PDF",1790161863,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9373cce2366272f0f542d912efccb08.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53d0fa4095eea04209615e02c1cc3c54.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f8c2dbeabfa9ef31536d15bae957060.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/332826f487edc88305f1cec738b8578b.webp",980,1385]